ArticleCureus2024
Association of COVID-19 With Emergence of Comorbidities: A Hospital-Based Cohort Study.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn 2019, the emergence of SARS-CoV-2 marked the beginning of the COVID-19 global pandemic, which reached its peak in 2020. Initially designated as a novel coronavirus, SARS-CoV-2 emerged as a respiratory illness and later began causing multi-organ complications in recovered patients.
methodsThis article presents a hospital-based retrospective cohort study conducted via telephone interviews with patients in a tertiary hospital. After obtaining verbal consent from the subjects, the study utilized a semi-structured questionnaire to gather data.
resultsIn the 54-person cohort group, 64.8% were males and 35.1% were females. The mean duration of the male patients' hospital stays was greater than that of the female patients. However, the mean lag time between the onset of comorbidities and recovery from COVID-19 was shorter in females than in males. Upon further analysis, it was revealed that female patients are more susceptible to the development of multiple comorbidities at once, occurring in 37.5% of the female patients in this study. Diabetes mellitus alone had the highest incidence rate (12.9%), followed by ST-elevation myocardial Infarctions (7.4%) and thrombocytopenia (5.5%). Of the cohort group, 51.8% developed comorbidities after exposure to COVID-19, while about 14.8% of the control group developed comorbidities from March 2020 onwards, i.e. from the commencement of the COVID-19 global pandemic. The relative risk assessed for this study is 3.5. The study's attributable risk is 71.42%.
conclusionThe incidence of comorbidities in the cohort group was greater than that in the control group, demonstrating COVID-19 as a risk factor for post-exposure comorbidities. It is clear that there is a direct association between COVID-19 and the development of comorbidities, which is inferred with a relative risk of 3.5.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.